Table 1.
Chlamydia pn IgA−, IgG− |
Chlamydia pn IgA−, IgG + |
Chlamydia pn IgA + , IgG + |
|
---|---|---|---|
N | 145 (35.5%) | 193 (47.5%) | 68 (17%) |
Gender (F, %) | 68 | 63 | 49*## |
Age (years) | 47 ± 16 | 51 ± 17* | 57.5 ± 13***# |
Age of onset (years) | 34 ± 22 | 35 ± 22 | 39 ± 22 |
Asthma duration (years) | 8 (1–23) | 10 (3–26) | 14.5 (2.5–25)* |
BMI (Kg/m2) | 26.5 (22.6–29.4) | 27 (23.4–30.9) | 26.4 (23.3–30) |
Tobacco | |||
Smokers (%, PY) | 12.4 (13 (0.3–60) | 18.1 (21 (1.4–58) | 19.1 (25 (4–68) |
Ex-smokers (%, PY) | 27.6 (9 (0.2–75) | 25.9 (16 (0.8–83) | 35.3 (22 (0.8–75) |
Non-smokers (%) | 60 | 56 | 46 * |
Environment | |||
City (%) | 24 | 23 | 27 |
Country side (%) | 38 | 44 | 47 |
Suburban (%) | 30 | 26 | 22 |
Atopy (Y, %) | 50 | 50 | 49 |
Exacerbations (n) | 0.88 ± 1.70 | 0.86 ± 1.60 | 1.06 ± 2.04 |
Classification | |||
Mild (%) | 56 | 55 | 38*# |
Moderate (%) | 16 | 19 | 29* |
Severe (%) | 28 | 26 | 31 |
Dose of ICS (equivalent of beclomethasone) | 760 ± 825 | 795 ± 1034 | 1022 ± 1042* |
Oral corticoids (Y, %) | 10 | 11 | 10 |
Biologics (Y, %) | 5 | 3 | 0 |
Anti-IgE (n) | 1 | 2 | 0 |
Anti-IL5 (n) | 4 | 2 | 0 |
Long-term macrolides (Y, %) | 2 | 0.5 | 3 |
Antileukotrienes (Y, %) | 23 | 29 | 29 |
ACT | 15.5 ± 5.2 | 15.5 ± 5.6 | 14.5 ± 0.7 |
ACQ | 1.88 ± 1.16 | 1.99 ± 1.30 | 2.19 ± 1.13 |
AQLQ | 4.61 ± 1.41 | 4.52 ± 1.48 | 4.29 ± 1.28 |
Results are presented as mean + SD for categorial variables and median (IQR) for skewed distribution. *: Significantly different from IgA-IgG-group
*: Different from IgA−/IgG−. #: Different from IgA− IgG +
*p < 0.05
**p < 0.001
***p < 0.0001
#p < 0.05
##p < 0.001
###p < 0.0001